No effective therapy is available for advanced hepatocellular carcinoma (liver cancer), it’s a terminal condition. Over 18,000 people typically die from it in the USA each year. It is much more common in Africa and East Asia where the risk of infection from Hepatitis B and C is much higher, which are associated with increased [...]
Entries Tagged as 'market trends'
Improving survival in Liver Cancer – at what cost?
July 28th, 2008 · No Comments · cancer, competitive intelligence, health, liver cancer, market trends, oncology, pharma, strategy
Tags:
15 minutes of fame in oncology
July 23rd, 2008 · No Comments · Cougar, cancer, company news, competitive intelligence, market intelligence, market trends, oncology, prostate
Wow, my blog on abiraterone in advanced prostate cancer got picked up last night by TopUSAsites for prostate cancer. It looks like the drug is going to be a hot topic for a while, but caution against the hype is advised until we see whether reduction in PSA and tumour shrinkage actually translates to what [...]
Tags:
A cancer patient’s inspiring story
July 20th, 2008 · No Comments · NHL, cancer, competitive intelligence, market intelligence, market trends, oncology, radioimmunotherapy, rituxan, targeted therapy
A lady who was diagnosed with non-Hodgkin’s lymphoma (NHL) and relapsed on chemotherapy, tells her story about how she overcame the odds with a promising new approach called radioimmunotherapy: VIDEO There is always hope around the corner with new treatments coming on the market.
Tags:
Cediranib (AZD2171) in Glioblastoma and brain cancer
July 14th, 2008 · No Comments · FGF, Tie-2, brain cancer, cancer, competitive intelligence, glioblastoma, market intelligence, market trends, oncology
The investigational drug AZD2171 (cediranib) from Astra-Zeneca may help shrink tumours and prolong survival of patients with a relatively common, aggressive type of brain cancer. In a phase II study of 31 patients with recurrent glioblastoma, researchers observed that daily treatment with cediranib decreased tumour volume by more than half in 56 percent of patients. [...]
Tags:
New treatment option for patients with liver cancer
July 2nd, 2008 · No Comments · FLT3, VEGF inhition, c-Kit, cancer, competitive intelligence, liver cancer, market intelligence, market trends, oncology
Treatment with sunitinib (Sutent) slows tumour growth and reduces the risk of metastasis in patients with hepatocellular carcinoma, an aggressive cancer of the liver. Hepatocellular carcinoma is a cancer that relies heavily on blood vessels for growth; sunitinib controls the growth of blood vessels and could therefore potentially play an important role for treatment. Image [...]
Tags:
Cervical cancer vaccines
June 22nd, 2008 · No Comments · cancer, cervical cancer, company news, competitive intelligence, market intelligence, market trends, skin cancer
The UK has recently approved a second vaccine that protects against HPV called Cervarix from GSK, in addition to Gardasil from Merck. Both vaccines protect against HPV, but Gardasil also protects against gentical warts, which Cervarix does not. Male with genital warts – image courtesy of Wikipedia The wholesale price for the two is exactly [...]
Tags:
Are Her2 inhibitors an alternative to chemo in breast cancer?
June 11th, 2008 · 1 Comment · breast cancer, cancer, competitive intelligence, market intelligence, market trends, oncology, pipeline
Image via WikipediaSeveral studies exploring the use of lapatinib (Tykerb, GlaxoSmithKline) in metastatic breast cancer have suggested that it may offer an alternative to chemotherapy in this setting, both as monotherapy, and in combination with other targeted therapies. One study explored the use of lapatinib alone, whereas others investigated combinations with trastuzumab (Herceptin, Genentech/Roche), with [...]
Tags:
Erbitux extends overall survival by 5 weeks in lung cancer
June 2nd, 2008 · No Comments · cancer, company news, competitive intelligence, lung cancer, market intelligence, market trends, oncology
ImClone announced that late-stage study data showed that first-line treatment with Erbitux (cetuximab) plus standard chemotherapy significantly increased overall survival by about five weeks in patients with advanced non-small cell lung cancer (NSCLC), compared with chemotherapy alone. The results were presented at the American Society of Clinical Oncology (ASCO) meeting this weekend. To put things [...]
Tags:
Study showed Alimta improved survival in certain types of Non-Small Cell Lung Cancer
May 28th, 2008 · No Comments · NSCLC, cancer, competitive intelligence, lung cancer, market intelligence, market trends, oncology
The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published online in the Journal of Clinical Oncology. NSCLC is the most common type of lung cancer and represents 85 to 90 percent of all lung [...]
Tags:
Market trends: cancer vs. ophthalmology drugs
May 14th, 2008 · No Comments · company news, competitive intelligence, market intelligence, market trends, oncology, ophthalmology
Today I was at the ophthalmologists office getting my eyes tested for some new glasses. The technician and I were chatting convivially about the pros and cons of Avastin versus Lucentis for wet age-related macular degeneration (AMD). Later, while looking at the National Institutes of Health (NIH) site on the internet, I noticed they have [...]
Tags: